Bristol Myers Squibb

We’re advancing research that looks at the biology of pulmonary fibrosis (PF) – with the goal of making a bigger difference for people living with this disease. Today’s treatments can slow the loss of lung function, but many people still need better options. One area we’re investigating is a target called lysophosphatidic acid receptor 1 (LPA1). Learn more: https://bit.ly/4uTyeHq #ATS2026 #OneBMS

Our teams are focused on developing therapies that aim to modify the course of disease and help address symptoms for people living with neurological and psychiatric conditions. We look forward to connecting with peers at the American Psychiatric Association Annual Meeting to exchange insights and explore scientific advancements in the field. Learn more about our neuroscience research: https://bit.ly/4eIOHt6 #APAAM26 #OneBMS

Scientific progress is built on persistence. It’s the drive to keep learning, keep improving and keep pushing forward, even when breakthroughs don’t come easily. We’re advancing research by combining human ingenuity with AI and emerging technologies to help bring new medicines to patients faster. It’s how we stay focused on what matters most and why We Won’t Lose. See how we’re focusing on the science most likely to make a meaningful difference for patients: https://bit.ly/3Rr6Thb #ScienceFirsthand #OneBMS #BMSWontLose

We believe people living with pulmonary fibrosis deserve more options, and we’re working to make that a reality. Our scientists continue to pursue innovative approaches that target the root cause of the disease, aimed at addressing unmet needs and bringing new hope to patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Learn more about #PulmonaryFibrosis: https://bit.ly/4tERS8Z #ATS2026 #OneBMS

A stroke can change your life in an instant — Dr. ShantaQuilette (Dr. Q) Develle, MBA, CPLC, MH, EA, knows this firsthand after experiencing a severe stroke that reshaped her daily life and perspective. In partnership with Johnson & Johnson Innovative Medicine, we’re committed to progressing research that addresses the profound impact stroke has on patients and families. During #StrokeMonth, hear ShantaQuilette’s story and why advancing stroke care remains critical: https://bit.ly/3QFWtdi #OneBMS

Science, standards, access: turning MRD into clinical impact   Last week, BMS hosted the GUIDE.MRD 4th General Assembly in Boudry at the BMS Collaboration Hub—bringing together academia, patient organizations, pharma, hospitals and diagnostics/technology partners to accelerate ctDNA-based minimal residual disease (MRD) testing in solid tumors. Guide.mrd is an IHI public-private consortium advancing ctDNA-based MRD testing in lung, pancreatic and colorectal cancers.   A big thank you to our panelists Anne Kerber, Lidewij Eva Vat (The Synergist.org), Klaus Pantel (Universitätsklinikum Hamburg Eppendorf), Andrew Slatter (Illumina) and Chiara Antoniani (Lung Cancer Europe) as well as to all consortium partners — for the open exchange and continued collaboration. What a productive session with patients in mind. What a fantastic team !   #CancerResearch #OneBMS #BMSSwitzerland

As both a Bristol Myers Squibb employee and someone living with psoriatic arthritis, Jennifer brings a powerful dual perspective. Her story highlights the real-world impact of chronic, immune-mediated diseases, like psoriatic arthritis, and the importance of advancing research to help address persistent unmet needs for patients. Learn more about Jennifer’s journey with psoriatic arthritis: https://bit.ly/3PBfRrA #OneBMS

Psoriatic arthritis (PsA) remains a complex challenge for those living with the disease, impacting joints, skin and everyday life. We’re advancing research to help address the unmet needs that exist. Learn more: https://bit.ly/4tnxid6 #OneBMS

The brain shapes how we think, feel and behave. Understanding it can help change what’s possible for those living with neurological conditions. Evans "John" Burford, senior scientist, shares what drives his work in neuroscience: advancing our understanding of how changes in the brain disrupt communication, function and daily life and how that research informs BMS’ commitment to neurological conditions and the patients impacted by them. Explore how we’re advancing neuroscience research: https://bit.ly/4tp14OD #ScienceFirsthand #OneBMS

Ready, set, run! 🏃♂️   13 colleagues from our Steinhausen office laced up their running shoes and took part in this year’s B2B Company Run in Zug.   Since 2022, this event has become a true tradition for us. No matter the conditions, we show up, run together and celebrate what really counts: team spirit, shared motivation and the energy of doing something as ONE TEAM.   #B2Run #OneBMS #BMSSwitzerland Jérome Garcin